Group I (n = 25) | Group II (n = 25) | Group III (n = 20) | Test of Sig. | p | |
---|---|---|---|---|---|
Age (yrs) | |||||
Median (Min. – Max.) | 40 (30-62) | 43.5(26-58) | 50 (41-55) | F =3.008 | 0.056 |
Mean ± SD. | 44± 10.5 | 43.3± 9.7 | 49.8± 5 | ||
Sex | |||||
Male | 2 (8%) | 8 (32%) | 9 (45%) | χ2=8.16* | 0.017* |
Female | 23 (92%) | 17 (68%) | 11 (55%) | ||
ARD | |||||
RA | n=15 | - | n= 9 | - | - |
SLE | n= 10 | - | n=11 | - | - |
LPD subtypes | |||||
HL | - | n= 7 | -- | - | - |
B-CLL | - | n= 10 | n= 6 | - | - |
NHL | - | n= 8 | n=12 | - | - |
DLBCL | - | 6 | 7 | - | - |
MCL | - | - | 1 | - | - |
FL | - | 1 | 1 | - | - |
T-cs lymphoma | - | 1 | 3 | - | - |
Castleman’s disease | - | - | n= 2 | - | - |
Duration of ARD (yrs) | |||||
Median (Min. – Max.) | 9 (6-18) | – | 10 (2-13) | U =202.0 | 0.440 |
Mean ± SD. | 18 ± 10.2 | – | 13 ± 8.9 | ||
Duration of LPD (yrs) | |||||
Median (Min. – Max.) | – | 7.5 (6-12) | 2 (1-10) | U =40.0* | <0.001* |
Mean ± SD. | – | 7.9 ± 1.8 | 3.3 ± 2.8 | ||
Activity score | |||||
DAS28 (for RA) | 3-5 | - | 5.1-7 | ||
BILAG-2004 (for SLE) | 8-12 | >12 | |||
Joint affected | |||||
Small | 18(72%) | 5(20%) | 13(65%) | χ2 =15.60 | <0.001* |
Small and Large | 7(28%) | 20(80%) | 7 (35%) | ||
LN enlargement | 1(4%) | 17(68%) | 14 (70%) | χ2 =27.29 | <0.001* |
HSM | 1(4%) | 11 (44%) | 7(35%) | χ2 =11.00 | 0.004* |
Pancytopenia | 2(8%) | 12(48%) | 9 (45%) | χ2 =10.94 | 0.004* |
B-symptomsa | 2(8%) | 15 (60%) | 14(70%) | χ2 =21.20 | <0.001* |